PACE-CME

Advancing insights into Lp(a) as a causal factor in CVD

Advancing insights into Lpa as a causal factor in CVD
RestartResume
    3' education - June 29, 2018 - John Chapman - Paris, France
    • Overview

      Elevated Lp(a) is now officially considered a genetically determined risk factor for CVD in the USA. Chapman summarizes how Lp(a) is atherogenic and how novel therapies may target this process.

    • Faculty

      John Chapman is Research Professor at the Pierre and Marie Curie University, and Director Emeritus of the National Institute for Health and Medical Research (INSERM) at the Pitié-Salpêtrière University Hospital in Paris, France.

    • Disclosures

      This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenters and do not necessarily reflect the views of PACE-cme.

      The content is aimed for medical professionals. To view this item member registration is needed. Register for free to get unlimited access to our educational resources.
      The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

    Facebook Comments

    Register

    We’re glad to see you’re enjoying PACE-CME…
    but how about a more personalized experience?

    Register for free